Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Teams With OSU to Develop SELDI-Based Dx for Rare Blood Disorder

NEW YORK (GenomeWeb News) — Ciphergen Biosystems today said it has struck an agreement with the Ohio State University Research Foundation to develop and validate a test to help detect the blood disease thrombotic thrombocytopenic purpura.
The partnership aims to discover a clinical diagnostic test that can “rapidly detect” deficiencies in the enzyme activity associated with the disorder, commonly called TTP, which affects blood coagulation.
Under the agreement, Ciphergen will work with OSURF to develop an assay to measure enzyme and antibody inhibition activity that they will test together in a series of multi-center studies.
Ciphergen CSO Eric Fung said it will use a SELDI-based test for “accurately measuring the product of enzymatic chain reaction that underlies the disease” in order to help doctors manage the disease and the effects of treatment.
Financial terms of the agreement were not released.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.